Suggestions
Kush Parmar, M.D., Ph.D.
Managing Partner at 5AM Ventures
Kush Parmar, M.D., Ph.D., is an accomplished professional with a diverse educational background and extensive experience in the medical, finance, and biotechnology sectors.
He earned his M.D. from Harvard Medical School, a Ph.D. in Biomedical Sciences from Harvard University, and an A.B. in Molecular Biology from Princeton University.
Additionally, Kush Parmar pursued further education in finance at Harvard Business School and completed the M.D., HST Program at the Massachusetts Institute of Technology.
Throughout his career, he has held prominent roles in various organizations, showcasing his leadership and expertise in the industry.
Some of his notable positions include Co-Founder at Immuneel Therapeutics, Ltd., Board Member at Ensoma, Board of Directors at Rallybio, and Chairman of the Board of Directors at Entrada Therapeutics.
His involvement also extends to institutions like Penn Medicine, University of Pennsylvania Health System, where he served as a Research Council Member, and the Department of Molecular Biology at Princeton University, where he was part of the Advisory Council.
Kush Parmar's contributions to the field are further highlighted by his roles at organizations like Grace Science Foundation, 5AM Ventures, Vor Biopharma, Homology Medicines, Inc., and Audentes Therapeutics.
His diverse background and range of appointments underscore his comprehensive understanding of the healthcare, biotechnology, and finance industries, solidifying his reputation as a seasoned professional in the field.
Highlights
We are thrilled our portfolio company Escient Pharmaceuticals and its first-in-class medicines will be entering the hands of the committed developers at Incyte to maximize patient impact. 5AM Ventures and Andy Schwab enjoyed the close collaboration with TCG to build this company together. Congratulations to the CEO Joshua Grass and his entire team, as well our terrific syndicate partners NEA, Orbimed, Sanofi Ventures, Fore and others. Very grateful to the volunteers and patients who have been part of the early clinical studies. We are hopeful that these medicines will start to crack the evolutionary enigma of this MRGPR target class and bring major improvements to the lives of patients. Pablo Cagnoni
An exciting day for 5AM Ventures with the unveiling of Latigo Biotherapeutics, Inc. Non-opioid, effective options to address pain could be a game changer for society. I know the team is committed to trying to make that change happen. Congrats to my partner Deborah Palestrant who co-led the Series A and our close collaborators at Westlake Village BioPartners® and Foresite Capital, among others.
